The complex journey of targeting RAS in oncology

Abstract Given the prevalence of RAS mutations in various cancers, personalized therapeutic approaches, guided by molecular markers, are essential. Farnesyltransferase inhibitors (FTIs) have emerged as potential therapeutic options; however, they also face obstacles such as toxicity and limited effi...

Full description

Bibliographic Details
Published in:BMC Cancer
Main Authors: Katarzyna Wasiak, Damian Ciunowicz, Amelia Kierasińska-Kałka, Marta Węgierska, Marcin Pacholczyk, Piotr Rieske, Ewelina Stoczyńska-Fidelus
Format: Article
Language:English
Published: BMC 2025-07-01
Subjects:
RAS proteins
KRAS
HRAS
NRAS
Oncogene
Cancer
Online Access:https://doi.org/10.1186/s12885-025-14033-y

Internet

https://doi.org/10.1186/s12885-025-14033-y

Similar Items